Skip to content

Postprandial glycemic response, glycemic index, and glycemic load of common staples and individual variations

Postprandial glycemic response, glycemic index, and glycemic load of common staples and individual variations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500108750
Enrollment
Unknown
Registered
2025-09-04
Start date
2025-09-06
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Group 1:White rice - Brown rice - Glucose
Group 2:White rice - Glucose - Brown rice
Group 3:Brown rice - White rice - Glucose
Group 4:Brown rice - Glucose - White rice
Group 5:Glucose - White rice - Brown rice
Group 6:Glucose - Brown rice - White rice

Sponsors

China Agricultural University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-45 years (inclusive); 2.Both genders eligible; 3.Individuals with normal digestive function (i.e., non-dyspeptic) or those with postprandial distress syndrome (planned recruitment: 15 participants with normal digestive function and 15 with postprandial distress syndrome); 4.Normal glycemic status or prediabetes; 5.Voluntary participation with signed informed consent; 6.Ability to perform light physical activities in the morning and maintain predominantly sedentary behavior during the 14-day period, with no physical education classes; 7.Habitual breakfast consumers willing to accept white rice, brown rice, and glucose solution as test meals; 8.Commitment to maintain regular sleep patterns (before 12:00 AM) without night-time sleep deprivation during the trial.

Exclusion criteria

Exclusion criteria: 1.Pregnancy, lactation, or diagnosis of major systemic diseases (including malignancies and severe psychiatric disorders). Strict exclusion of organic gastrointestinal pathologies including but not limited to: gastric cancer, colorectal cancer, gastroesophageal reflux disease, esophagitis, esophageal carcinoma, peptic ulcers, Crohn's disease, intestinal obstruction, inflammatory bowel disease, hepatitis, cirrhosis, hepatocellular carcinoma, cholelithiasis, cholecystitis, cholangitis, cholangiocarcinoma, pancreatitis, pancreatic cancer, peritonitis, and abdominal hernias. 2.History of diabetes mellitus or known genetic syndromes/diseases affecting glucose tolerance (e.g., glucose-6-phosphate dehydrogenase deficiency, polycystic ovary syndrome). 3.Use of medications known to interfere with glucose tolerance within the preceding month (including thiazide diuretics, corticosteroids, spironolactone). 4.Administration of medications affecting appetite or gastrointestinal function within the past 30 days. 5.Recent (within 1 month) use of antibiotics or probiotics. 6.Active participation in weight loss programs. 7.Tobacco smoking or chronic alcohol abuse. 8.Inability to operate smartphones or unwillingness to wear continuous glucose monitoring devices. 9.Concurrent enrollment in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Postprandial glucose area under the curve;Peak postprandial blood glucose;

Secondary

MeasureTime frame
Time to peak blood glucose;Time to return to fasting blood glucose level;Number of blood glucose peaks;Maximum blood glucose excursion;Glycemic index;Glycemic load;

Countries

China

Contacts

Public ContactRuixin Zhu

China Agricultural University

zhuruixin07@126.com+86 10 6273 0004

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026